SurfSubQ
What it found
No result yet.
What was tested
Treatment tested
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC
Month 12
Quality of life (reported by participants)
Other measures (18)
Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After the First Injection and After 6 Months Assessed Using TASQ-SC
Baseline, Month 6
Quality of life (reported by participants)Change From Baseline in NfL Protein Levels in Serum
Baseline, Month 6, Month 12
Blood or spinal fluid markersConcentration of NfL Protein Levels in Serum
Baseline, Month 6, Month 12
Blood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With MS Relapse
Up to Month 12
RelapsesBlood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With Expanded Disability Status Scale (EDSS)
Up to Month 12
Disability progressionBlood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With Previous MS Disease Modifying Therapy (DMT)
Up to Month 12
Blood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With NfL Confounder - Serum Creatinine
Up to Month 12
Blood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With NfL Confounder - Co-morbidities
Up to Month 12
Blood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With NfL Confounder - Age
Up to Month 12
Blood or spinal fluid markersCorrelation Between NfL Protein Levels in Serum With NfL Confounder - Body Mass Index [BMI]
Up to Month 12
Blood or spinal fluid markers
Who could take part
Relapsing and progressive · 18 and over
Inclusion Criteria: * Diagnosis of MS * RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024 * First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab Exclusion Criteria: * Participation in interventional studies investigating DMTs for MS * Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site * Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®) * Severe psychiatric disability * Pregnant women
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
Loading reviews and guidelines…
Linked trials
Refers to
NIS MoOzaRtPhase 4 · Completed (inferred)
Links found where a registry record names another trial's registry number.
Related trials
- An Open-Label, Single-Arm Clinical Study to Evaluate the …
Early phase 1 · Not yet recruiting
Still running
- Exploration of Novel Imaging Biomarkers on OCT for Ublitu…
Not a drug-phase study · Recruiting
Still running
- People With Multiple Sclerosis Treated With Ocrelizumab a…
Recruiting
Still running
- PORTAMENTO
Phase 2 · Running, not recruiting
Still running
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetic…
Phase 4 · Running, not recruiting
Still running
- FNO-RS2-OCREPRIPRO
Phase 4 · Recruiting
Still running
History
Started
Sept 2024
Main results due
Mar 2028
Finished
Mar 2028
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error